ConductScience.org, home

Paper6901593

Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance.

Mandell GL and 1 other. Antimicrob Agents Chemother, 1980. Cited by 63 papers, by iCite.

Cite this record

ConductScience Library. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Papers, record 6901593. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6901593

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1980
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
63
iCite
Relative citation ratio, by iCite
2.87
iCite
Revised in PubMed
2021-05-26
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mandell GLG L
2Moorman DRD R

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RifampinMajor topic
Staphylococcal InfectionsMajor topic
Acute Disease
Animals
Drug Synergism
Drug Therapy, Combination
Male
Methicillin
Mice
Microbial Sensitivity Tests
Penicillin Resistance
Penicillins
Trimethoprim

Source PubMed

Download CSV of topics

References6

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15776003Bacteriologic studies of rifampin, a new semisynthetic antibiotic.J Infect Dis1969https://conductscience.org/library/papers/5776003PubMed
25023643Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies.J Infect Dis1972https://conductscience.org/library/papers/5023643PubMed
34718959Interaction of intraleukocytic bacteria and antibiotics.J Clin Invest1973https://conductscience.org/library/papers/4718959PubMed
44790559Treatment of experimental staphylococcal infection with rifampin.Antimicrob Agents Chemother1972https://conductscience.org/library/papers/4790559PubMed
51117067Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro and in vivo studies with emphasis on staphylococcal--leukocyte interaction.J Clin Invest1975https://conductscience.org/library/papers/1117067PubMed
6666300In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus.Antimicrob Agents Chemother1978https://conductscience.org/library/papers/666300PubMed

Download CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 63 citations.

PMIDTitleJournalYearIn PapersSource
40392929Sulfamethoxazole-trimethoprim plus rifampicin combination therapy for methicillin-resistant Staphylococcus aureus infection: An in vitro study.PLoS One2025https://conductscience.org/library/papers/40392929PubMed
31106377Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial.J Antimicrob Chemother2019https://conductscience.org/library/papers/31106377PubMed
28245229Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection.PLoS One2017https://conductscience.org/library/papers/28245229PubMed
24514089Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection.Antimicrob Agents Chemother2014https://conductscience.org/library/papers/24514089PubMed
22553438Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin.Can J Infect Dis1990https://conductscience.org/library/papers/22553438PubMed
20065324Rifampin combination therapy for nonmycobacterial infections.Clin Microbiol Rev2010https://conductscience.org/library/papers/20065324PubMed
16495239In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.Antimicrob Agents Chemother2006https://conductscience.org/library/papers/16495239PubMed
11897604Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/11897604PubMed
8257135Influence of rifampin on fleroxacin pharmacokinetics.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8257135PubMed
7325636Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/7325636PubMed
7127231Rifampin therapy for Staphylococcus epidermidis endocarditis.Can Med Assoc J1982https://conductscience.org/library/papers/7127231PubMed
6859835In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus.Antimicrob Agents Chemother1983https://conductscience.org/library/papers/6859835PubMed
6732212Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus.Antimicrob Agents Chemother1984https://conductscience.org/library/papers/6732212PubMed
3957435Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus.Infection1986https://conductscience.org/library/papers/3957435PubMed
3707110Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.Antimicrob Agents Chemother1986https://conductscience.org/library/papers/3707110PubMed
3031442Antimicrobial resistance of Staphylococcus aureus: genetic basis.Microbiol Rev1987https://conductscience.org/library/papers/3031442PubMed
2719468In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2719468PubMed
2675760Methicillin-resistant staphylococci: detection methods and treatment of infections.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2675760PubMed
2128441Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2128441PubMed
2014980Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/2014980PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6901593

GET https://conductscience.org/api/papers/v1/6901593/cited_by?page=2